Read by QxMD icon Read


Bo Zhang, Shuyuan Wang, Jie Qian, Wenjia Yang, Fangfei Qian, Jun Lu, Yanwei Zhang, Rong Qiao, Baohui Han
BACKGROUND: Two or more different epidermal growth factor receptor (EGFR) mutations can be detected within a single tumor sample, which represents complex mutations. However, the frequency and efficacy of tyrosine kinase inhibitor (TKI) treatments for patients harboring these mutations are unknown. METHODS: From January 2011 to January 2017, patients diagnosed with EGFR mutations were screened. The effectiveness of TKIs in patients with complex mutations was retrospectively analyzed...
March 15, 2018: Cancer
Steven Lehrer, Peter H Rheinstein, Kenneth E Rosenzweig
No abstract text is available yet for this article.
March 15, 2018: Cancer
Sarah Sloot, Yian A Chen, Xiuhua Zhao, Jamie L Weber, Jacob J Benedict, James J Mulé, Keiran S Smalley, Jeffrey S Weber, Jonathan S Zager, Peter A Forsyth, Vernon K Sondak, Geoffrey T Gibney
No abstract text is available yet for this article.
March 15, 2018: Cancer
Areej El-Jawahri, Sarah R Fishman, Julie Vanderklish, Don S Dizon, Nicole Pensak, Lara Traeger, Joseph A Greer, Elyse R Park, Netana Markovitz, Lauren Waldman, Chrisa Hunnewell, Meredith Saylor, Jessica Driscoll, Zhigang Li, Thomas R Spitzer, Steven McAfee, Yi-Bin Chen, Jennifer S Temel
BACKGROUND: Although sexual dysfunction is common after hematopoietic stem cell transplantation (HCT), interventions to address sexual function are lacking. METHODS: We conducted a pilot study to assess the feasibility and preliminary efficacy of a multimodal intervention to address sexual dysfunction in allogeneic HCT survivors. Transplant clinicians screened HCT survivors ≥3 months post-HCT for sexual dysfunction causing distress. Those who screened positive attended monthly visits with a trained transplant clinician who: 1) performed an assessment of the causes of sexual dysfunction; 2) educated and empowered the patient to address his or her sexual concerns; and 3) implemented therapeutic interventions targeting the patient's needs...
March 14, 2018: Cancer
Carole Fakhry, Martin Krapcho, David W Eisele, Gypsyamber D'Souza
BACKGROUND: The increasing incidence of oropharyngeal squamous cell cancer (OPSCC) is well established. However, up-to-date incidence estimates and trends for head and neck squamous cell cancers (HNSCCs) overall, including major anatomic sites, and nonoropharyngeal (non-OP) HNSCCs by sex, race, and age in the United States are not well described. METHODS: A retrospective analysis of incident HNSCCs during 1992 through 2014 using the Surveillance, Epidemiology, and End Results database was performed to evaluate the incidence of HNSCCs overall, OPSCC, and non-OP HNSCC (those of the larynx, oral cavity, hypopharynx, nasopharynx, and nasal cavity)...
March 13, 2018: Cancer
Glenwood D Goss, Everett E Vokes, Michael S Gordon, Leena Gandhi, Kyriakos P Papadopoulos, Drew W Rasco, JuDee S Fischer, Katharine L Chu, William W Ames, Rajendar K Mittapalli, Ho-Jin Lee, Jiewei Zeng, Lisa A Roberts-Rapp, Lise I Loberg, Peter J Ansell, Edward B Reilly, Christopher J Ocampo, Kyle D Holen, Anthony W Tolcher
BACKGROUND: Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR-directed therapies have led to increased efficacy but are associated with specific side effects. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) targets EGFR with a monoclonal antibody linked to a cytotoxin, and is highly tumor-specific. METHODS: This phase 1/2 study evaluated the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors with known wild-type EGFR overexpression, amplification, or mutated EGFR variant III...
March 13, 2018: Cancer
Daniel Lin, Heather T Gold, David Schreiber, Lawrence P Leichman, Scott E Sherman, Daniel J Becker
BACKGROUND: Although outcomes for patients with squamous cell carcinoma of the anus (SCCA) have improved, the gains in benefit may not be shared uniformly among patients of disparate socioeconomic status. In the current study, the authors investigated whether area-based median household income (MHI) is predictive of survival among patients with SCCA. METHODS: Patients diagnosed with SCCA from 2004 through 2013 in the Surveillance, Epidemiology, and End Results registry were included...
March 12, 2018: Cancer
Neeraj Agarwal, Sumanta K Pal, Andrew W Hahn, Roberto H Nussenzveig, Gregory R Pond, Sumati V Gupta, Jue Wang, Mehmet A Bilen, Gurudatta Naik, Pooja Ghatalia, Christopher J Hoimes, Dharmesh Gopalakrishnan, Pedro C Barata, Alexandra Drakaki, Bishoy M Faltas, Lesli A Kiedrowski, Richard B Lanman, Rebecca J Nagy, Nicholas J Vogelzang, Kenneth M Boucher, Ulka N Vaishampayan, Guru Sonpavde, Petros Grivas
BACKGROUND: Biomarker-guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell-free circulating DNA (cfDNA) next-generation sequencing (NGS) readily available in the clinic. The objective of the current study was to determine whether the genomic profile of mUC detected by NGS of cfDNA is similar to historical tumor tissue NGS studies...
March 8, 2018: Cancer
I-Chan Huang, Conor M Jones, Tara M Brinkman, Melissa M Hudson, D Kumar Srivastava, Yuelin Li, Leslie L Robison, Kevin R Krull
BACKGROUND: To the authors' knowledge, social network status in adolescent and young adult (AYA) cancer survivors has not been adequately studied to date. The authors developed and validated a functional social network index (FSNI) for AYA survivors, and compared its performance with that of 2 traditional indices (density and betweenness centrality). METHODS: A total of 102 AYA survivors and 102 noncancer controls who were matched for age, sex, and race were recruited from an Internet panel...
March 8, 2018: Cancer
Li Xuan, Yu Wang, Fen Huang, Erlie Jiang, Lan Deng, Bingyi Wu, Zhiping Fan, Xinquan Liang, Na Xu, Jieyu Ye, Ren Lin, Changxin Yin, Yuanyuan Zhang, Jing Sun, Mingzhe Han, Xiaojun Huang, Qifa Liu
BACKGROUND: The objective of this study was to evaluate the effect of sorafenib on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: A total of 144 patients with FLT3-ITD AML undergoing allo-HSCT between January 2012 and December 2015 were enrolled in this study. Depending on whether they were receiving sorafenib before transplantation or sorafenib maintenance after transplantation, patients were divided into 4 groups: patients receiving sorafenib before transplantation (group A; n = 36), patients receiving sorafenib after transplantation (group B; n = 32), patients receiving sorafenib both before and after transplantation (group C; n = 26), and patients receiving sorafenib neither before nor after transplantation (group D; n = 50)...
March 6, 2018: Cancer
Denise Riedel Lewis, Huann-Sheng Chen, Myles G Cockburn, Xiao-Cheng Wu, Antoinette M Stroup, Douglas N Midthune, Zhaohui Zou, Martin F Krapcho, Daniel G Miller, Eric J Feuer
BACKGROUND: The National Cancer Institute's cancer incidence estimates through 2015 from the Surveillance, Epidemiology, and End Results (SEER) registries' November 2017 submission are released in April 2018. METHODS: Early estimates (February 2017) of cancer incidence rates and trends from the SEER 18 registries for diagnoses in 2000 through 2015 were evaluated with a revised delay-adjustment model, which was used to adjust for the undercount of cases in the early release...
March 6, 2018: Cancer
Hagop M Kantarjian, Yun Su, Elias J Jabbour, Helen Bhattacharyya, Eric Yan, Joseph C Cappelleri, David I Marks
BACKGROUND: Inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, demonstrated superior clinical activity versus standard-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO-VATE trial. The authors assessed patient-reported outcomes (PROs) from that study. METHODS: Patients were randomized to receive either InO (1.8 mg/m2 per cycle for ≤6 cycles) or SOC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor, or ara-C plus mitoxantrone, or high-dose ara-C for ≤4 cycles) and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline, on day 1 of each cycle, and at the end of treatment...
March 6, 2018: Cancer
Kendra L Schwartz, Michael S Simon, Lauren C Bylsma, Julie J Ruterbusch, Jennifer L Beebe-Dimmer, Neil M Schultz, Scott C Flanders, Arie Barlev, Jon P Fryzek, Ruben G W Quek
BACKGROUND: The current study was performed to describe patient characteristics, treatment patterns, survival, health care resource use (HRU), and costs among older women in the United States with advanced (American Joint Committee on Cancer stage III/IV) triple-negative breast cancer (TNBC) in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. METHODS: Women who were aged ≥66 years at the time of diagnosis and diagnosed with advanced TNBC between January 1, 2007, and January 1, 2011, in the SEER-Medicare database and who were followed for survival through December 31, 2013, were eligible...
March 5, 2018: Cancer
Fabio Efficace, Fausto Castagnetti, Bruno Martino, Massimo Breccia, Mariella D'Adda, Emanuele Angelucci, Fabio Stagno, Francesco Cottone, Alessandra Malato, Elena Trabacchi, Silvana Franca Capalbo, Marco Gobbi, Giuseppe Visani, Marzia Salvucci, Isabella Capodanno, Patrizia Tosi, Mario Tiribelli, Anna Rita Scortechini, Luciano Levato, Elena Maino, Gianni Binotto, Gabriele Gugliotta, Marco Vignetti, Michele Baccarani, Gianantonio Rosti
BACKGROUND: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health-related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib. METHODS: This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML...
March 2, 2018: Cancer
Andrew H Zureick, Casey L Evans, Andrzej Niemierko, Julie A Grieco, Alexandra J Nichols, Barbara C Fullerton, Clayton B Hess, Claire P Goebel, Sara L Gallotto, Elizabeth A Weyman, Dillon E Gaudet, Jessica A Nartowicz, David H Ebb, Robin M Jones, Shannon M MacDonald, Nancy J Tarbell, Torunn I Yock, Margaret B Pulsifer
BACKGROUND: Radiotherapy (RT) in the pediatric brain tumor population causes late neurocognitive effects. In the current study, the authors investigated associations between clinical and dosimetric risk factors and memory outcomes in a cohort of patients treated with proton radiotherapy (PRT). METHODS: A total of 70 patients (median age at PRT, 12.1 years [range, 5.0-22.5 years]) who were treated with PRT were identified with baseline and follow-up evaluations of visual and verbal memory (Children's Memory Scale and the third edition of the Wechsler Memory Scale)...
March 2, 2018: Cancer
Xiao-Feng Zhai, Xiao-Lin Liu, Feng Shen, Jia Fan, Chang-Quan Ling
BACKGROUND: To explore the clinical efficacy of traditional herbal medicine (THM) in the prevention of disease recurrence of small hepatocellular carcinoma after surgery, a prospective randomized controlled study was conducted between October 2006 and May 2010. The results indicated that THM prevented the recurrence of SHCC with an efficacy that was superior to that of transarterial chemoembolization (TACE) during a median follow-up of 26.61 months. METHODS: The patients were followed up every 6 months, and the clinical data before October 20, 2015 were analyzed...
March 2, 2018: Cancer
Caryn Mei Hsien Chan, Chong Guan Ng, Aishah Taib, Lei Hum Wee, Edward Krupat, Fremonta Meyer
No abstract text is available yet for this article.
March 2, 2018: Cancer
Marc A Dall'Era, Mary J Lo, Jaclyn Chen, Rosemary Cress, Ann S Hamilton
BACKGROUND: To the authors' knowledge, the survival benefit of local therapy in the setting of advanced prostate cancer remains unknown. The authors investigated whether prostate-directed treatment with either surgery or radiotherapy versus conservative treatment in the setting of locally advanced or metastatic disease was associated with improved survival within a cohort of men from the Centers for Disease Control and Prevention's (CDC) Breast and Prostate Cancer Data Quality and Patterns of Care Study (CDC POC-BP)...
March 2, 2018: Cancer
Rachel A Freedman, Nancy L Keating, Nancy U Lin, Eric P Winer, Ines Vaz-Luis, Joyce Lii, Pedro Exman, William T Barry
BACKGROUND: Although breast cancer often is perceived to be indolent in older women, breast cancer outcomes in the oldest patients are variable. In the current study, the authors examined breast cancer-specific death by age, stage, and disease subtype in a large, population-based cohort. METHODS: Using Surveillance, Epidemiology, and End Results data, a total of 486,118 women diagnosed with American Joint Committee on Cancer stage I to IV breast cancer between 2000 and 2012 were identified...
March 2, 2018: Cancer
Matthias Guckenberger, Reinhart A Sweeney, Maria Hawkins, Jose Belderbos, Nicolaus Andratschke, Merina Ahmed, Indira Madani, Frederick Mantel, Sabrina Steigerwald, Michael Flentje
BACKGROUND: The objective of this study was to prospectively evaluate dose-intensified hypofractionated stereotactic body radiation therapy (SBRT) in patients with painful spinal metastases in a multicenter, single-arm, phase 2 study. METHODS: Patients with 2 or fewer distinct, noncontiguous, painful, mechanically stable, unirradiated spinal metastases from a solid tumor with a Karnofsky performance status ≥ 60 were eligible. Patients with a long (Mizumoto score ≤ 4) or intermediate overall survival expectancy (Mizumoto score = 5-9) received 48...
March 2, 2018: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"